Xeris Biopharma Holdings Inc (XERS)

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®June 11, 2026 4:39 PM
Business Wire Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris’ commitment to the primary periodic paralysis community and the patients who rely on Keveyis Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance with respect to U.S. Patent Application No. 17/151,405, entitled “Compositions and Methods of Use.” The allowed claims in this application cover the use of the company’s KEVEYIS® (dichlorphenamide) product. The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability and is expected to issue as a U.S. patent following the completion of standard administrative steps. Following this issuance, the Company will submit the patent to the U.S. Food and Drug Administration (FDA) for listing in the FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the Orange Book. Assuming that all necessary actions are taken and all maintenance fees are paid, this new patent will provide intellectual property protection for KEVEYIS through 2039. “KEVEYIS is the first FDA-approved therapy for primary periodic paralysis, a rare and debilitating condition, and this Notice of Allowance reflects our long-standing commitment to this highly underserved patient community who depend on it,” said John Shannon, CEO of Xeris. “What we do matters. We fight for patients every day, and protecting and strengthening the intellectual property around KEVEYIS ensures we can continue to deliver this important therapy and comprehensive support for the primary periodic paralysis community for years to come.” KEVEYIS® (dichlorphenamide) is an FDA-approved treatment for primary periodic paralysis (PPP). KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. PPP is a rare genetic condition that affects muscles and causes episodes of muscle weakness and/or temporary paralysis that can be progressive and debilitating. KEVEYIS has been shown to reduce the number, severity, and duration of PPP attacks. For full prescribing information, including Important Safety Information, please visit www.keveyis.com. Important Safety Information Contraindications Hypersensitivity to dichlorphenamide or other sulfonamides Concomitant use of KEVEYIS and high-dose aspirin Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy Warnings and Precautions Hypersensitivity/Anaphylaxis/Idiosyncratic Reactions Fatalities associated with the administration of sulfonamides have occurred due to adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Pulmonary involvement can occur in isolation or as part of a systemic reaction. Discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or other life-threatening adverse reaction. Concomitant Use of Aspirin or Other Salicylates Carbonic anhydrous inhibitors, including KEVEYIS, can cause metabolic acidosis, which can increase the risk of salicylate toxicity. Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Use with caution and carefully monitor in patients receiving low-dose aspirin. Hypokalemia KEVEYIS increases potassium excretion and can cause hypokalemia. The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, and theophylline). Baseline and periodic measurements of serum potassium are recommended. If hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS and correction of potassium levels. Metabolic Acidosis KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis. Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of acidosis. Concomitant use of KEVEYIS in compensated patients with respiratory acidosis, such as in advanced lung diseases, may lead to respiratory decompensation. Baseline and periodic measurements of serum bicarbonate during KEVEYIS treatment are recommended. If metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS. Falls KEVEYIS increases the risk of falls; risk is greater in the elderly and with higher doses. Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS. Pregnancy and Lactation Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman. Adverse Reactions The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state. Please see Full Prescribing Information. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: RECORLEV®, for the treatment of endogenous Cushing’s syndrome; GVOKE®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and KEVEYIS®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for Xeris Biopharma Holdings, Inc., including statements regarding, the expected grant and scope of the U.S. patent for Keveyis, the company’s intention to submit the patent for listing in the FDA’s Orange Book, the term of intellectual property protection for Keveyis, the company’s intention to protect and strengthen its intellectual property rights relating to KEVEYIS®, commitment to protecting the long-term value of its assets, the growth potential of its drug products, including KEVEYIS®, the market and therapeutic potential of its products and product candidates, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its collaborators’ ability to protect its intellectual property and proprietary technology, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. View source version on businesswire.com: https://www.businesswire.com/news/home/20260611817161/en/ Investor Contact
Allison Wey
Senior Vice President, Investor Relations
awey@xerispharma.com Original: Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2026 4:15 PM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 304,975 shares of its common stock to 90 new employee(s) under Xeris’ Inducement Equity Plan.


Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.


About Xeris


Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.


Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260403376311/en/
Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com


Original: Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlookMarch 2, 2026 8:09 AM
IH Market News
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares gained nearly 3% in premarket trading on Monday after the company reported fourth-quarter results that topped analyst expectations and issued 2026 revenue guidance above consensus forecasts.The biopharmaceutical company posted adjusted earnings per share of $0.06 for the fourth quarter, exceeding analyst estimates of $0.02 by $0.04.Quarterly revenue came in at $85.81 million, beating the consensus forecast of $81.38 million and marking a 42.8% increase from $60.10 million in the same quarter last year. For full-year 2025, total revenue rose 43.7% year over year to $291.85 million, compared with $203.07 million in 2024.Xeris projected full-year 2026 revenue in the range of $375 million to $390 million. The midpoint of $382.5 million stands roughly 4% above analyst consensus estimates of $368 million. The company also expects adjusted EBITDA to increase in absolute terms compared with 2025, although research and development expenses are expected to rise by approximately $25 million as it launches a Phase 3 trial for XP-8121. Selling, general and administrative costs are also projected to increase by about $45 million, largely driven by continued investment in Recorlev.“2025 was a transformational year, marked by focused execution, record revenue growth, and our emergence as a self-funding, sustainable biopharmaceutical company,” said Chief Executive Officer John Shannon.Recorlev net revenue doubled year over year, rising 100.5% to $45.33 million in the fourth quarter, supported by growing patient demand. Gvoke net revenue increased 5.9% to $24.65 million due to improved net pricing, while Keveyis net revenue advanced 15.1% to $12.80 million, also driven by higher patient demand.For the full year 2025, Xeris reported net income of $0.55 million, compared with a net loss of $54.84 million in 2024. Adjusted EBITDA reached $59.42 million for the year, representing an improvement of $58.2 million from the prior period.

Original: Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlook

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement LawsuitFebruary 26, 2026 5:55 PM
Business Wire
Four Orange Book Listed Patents through March 2040


Orphan Drug Exclusivity through December 2028


Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jersey against Torrent Pharmaceuticals Limited (along with its affiliate) and Somerset Therapeutics, LLC (along with its affiliates), each of which filed an Abbreviated New Drug Application ("ANDA") with the U.S. Food and Drug Administration (the “FDA”) seeking approval to manufacture, use or sell a generic version of Recorlev® (levoketoconazole) (each, an “ANDA Filer”). Xeris’s complaint seeks an injunction to prevent the manufacture, use, and sale of a generic version of RECORLEV by each ANDA Filer until the expiration of Xeris’s patents in March 2040.


“We are confident in the quality and strength of the intellectual property we have developed for Recorlev,” said John P. Shannon, CEO of Xeris Biopharma. “We have filed this patent infringement lawsuit to vigorously defend our position.”


The complaint was filed following receipt of Paragraph IV Certification Notice Letters from the ANDA Filers (each a “Notice Letter”). In its respective Notice Letter, each ANDA Filer alleged that the four patents covering Recorlev that are listed in the FDA’s “Approved Drug Products with Therapeutic Equivalence Evaluations” (Orange Book), scheduled to expire in March 2040 (U.S. Patent Numbers 11,020,393, 11,278,547, 11,903,940, and 12,377,096), are invalid, unenforceable, or will not be infringed by the respective ANDA Filer's commercial manufacture, use, or sale of the generic levoketoconazole product described in its ANDA submission.


Xeris may receive additional Notice Letters in the future from ANDA filers seeking approval of a generic version of Recorlev and intends to enforce and defend its intellectual property rights relating to Recorlev. Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited are represented in this litigation by Latham & Watkins, LLP.


About Xeris


Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.


Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.


Forward-Looking Statements


Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for the Company, including statements, among other things, regarding its intention to enforce and defend its intellectual property rights relating to Recorlev®, including any expectations regarding the pending litigation, any plans to file a lawsuit against an ANDA filer in the future and the success or outcome of any such action, and its expectation that the Company will receive additional Notice Letters in the future. Because such statements are subject to risks and uncertainties, they constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of the Company’s experience and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect the Company can be found in the Company’s filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in the Company’s SEC filings are not the only risks the Company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. Forward-looking statements in this report are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260226546074/en/
Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com


Original: Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026February 17, 2026 7:30 AM
Business Wire
Conference Call to be Held at 8:30 a.m. ET


Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.


To pre-register for the call, please go to the following link:

https://events.q4inc.com/analyst/428274643?pwd=TZMrH35H


After pre-registering, a confirmation email will be sent. To join the live webcast, please visit “Events” on the Investor Relations page, or use this link: https://events.q4inc.com/attendee/428274643. The Company recommends registering a minimum of ten minutes prior to the start of the call. A replay of the conference call will be available on the Company’s Investor Relations site at: https://xerispharma.com/investor-relations.


About Xeris


Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.


Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260217718408/en/
Xeris Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com


Original: Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

MMMM Oh what a great race! Any good news coming?

XERS, new 52 week high

8 month trend is tremendously strong in this market!!

Seems a lot like all the hyped pump and dump stocks. I see the same hype from people posting but no results…..hmmmmmm

Monk things starting to take shape

We need to rebound to 3 first. Back to level. Normal And to 4. Is possible ..

XERS under $3

Still here👍

We are ready?🙏

ya..:)

Your welcome

Thankyou!

Not really sure, but there has been positive news on this company. My app tip ranks has a forecast $51!! I’m holding lol good luck

XERS...3.29 BREAK OUT COMING UP

Green lately..whats the catalysts?

Buy hold and don’t look back$$$$$

XERS new 52 week high

Let’s hope to break 3.00 soon

Izzy Englander likes $XERS...

https://finance.yahoo.com/news/billionaire-israel-englander-pulls-trigger-133848525.html

Anybody know what this is G85CVR010 ? It-showed-in-my-TD-acct-after

Strongbridge vanished and XERS showed up.


Thank you

Yes indeed

Nice catch in the low 2.00s.

Goodluck to all the Longs!

Ramping up for sure.

I like what I see here!

Looks like a Trend reversal

Great with patience!

Let’s go $XERS

#EG84

PDUFA New Years ?

They stalled the run when they first announced the merger, then silently listed their failed FDA trial in that q. They have more stuff in the pipeline and once the merger is done, maybe they can ramp revenue.

Can we make it rain here?

Premarket action .. nice news.


XERS

Where is the bottom to XERS? I grabbed a a couple hundred a few days ago and it just keeps dropping more an more. Even after the good news today and yesterday. I was hoping maybe someone had an opinion they would like to share. Also does anyone know the real OS or Float? When I look at the OTC website I see it hasn't been updated since March 22nd.

https://www.otcmarkets.com/stock/SLS/security

Thanks for any feed back. Much appreciated

Item 5.

Ownership of 5 Percent or Less of a Class. If this statement is being
filed to report the fact that as of the date hereof the reporting person
has ceased to be the beneficial owner of more than 5 percent of the
class of securities, check the following [ X ].

Blackrock sold 2.1m shares into it since their last filing in May until today. If they are done suppressing it now, maybe it can finally head north to where it belongs.

Company on verge of bullish long run consolidated after bull flag bo last 2 days, imo anything over 5.2
and this could easily hit 7.8, breaks that or news stock can easily reach double digits.

Nom nom nom bring the gains.

They are acquiring another company, which pushed the profitability timeline back and it reflected in that. That said, it'll cross the threshold a little harder. Some nice gains whether flipping or bottom feeding long.

Recent announcement of deal caused PT to go from $14 to $9.

You guys enjoying the start of this nice run?

Delicious.

Once these conversions clear the landscape will probably change quick. I would think we are close too, but...

Falcon stocks has them as a buy this week. Holding off yet. Maybe bottom is near.

So many conversions knocking the floor out of this thing. One day, pow, right in the kisser.

Conversions on this are still brutal. Float is low, one day she breaks the chains.

Must be looming conversions. Company events looking good.

Must be looming conversions. Company events looking good.

Good news out after hours. $$$